報價延遲最少15分鐘:2026/01/11 14:16 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.92 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
--/--
|
|
企業價值
23.01M
|
| 資產負債 |
|
每股賬面淨值
4.49
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements. |
